10 years and $100M-plus later, GSK shutters a China R&D site during a major pipeline overhaul
A decade ago, then GSK R&D chief Moncef Slaoui proudly unveiled a $100 million plan to build a big neurosciences research group in Shanghai. The …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
